Seely Lynn's Form 4 filing
Lyell Immunopharma, Inc. (LYEL) · filed Mar 18, 2025
- Accession no.
- 0001415889-25-008509
- Filed
- Mar 18, 2025
- Trade date
- Mar 14, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $106.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Seely LynnCIK 0001327111 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | Common Stock | PPurchaseAcquired | +175,000 | $0.61F1 | +$106,750 | 712,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.
Referenced by the price of 1 transaction in Table I.